证券代码：688076 证券简称：诺泰生物 公告编号：2025-043 江苏诺泰澳赛诺生物制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 23 日 （二） 股东大会召开的地点：浙江省杭州市余杭区文一西路 1378 号杭州师范大 学科技园 E 座 12 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 161 | | --- | --- | | 普通股股东人数 | 161 | | 2、出席会议的股东所持有的表决权数量 | 117,810,044 | | 普通股股东所持有表决权数量 | 117,810,044 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.39 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比 ...

经全体与会监事审议，本次会议以投票表决方式审议通过了以下议案： 一、审议通过了《关于选举监事会主席的议案》 根据《公司章程》的规定，经各位监事讨论，同意选举殷新波先生为公司第 四届监事会主席，任期自本次监事会审议通过之日起至第四届监事会届满之日止。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 江苏诺泰澳赛诺生物制药股份有限公司监事会 证券代码：688076 证券简称：诺泰生物 公告编号：2025-044 江苏诺泰澳赛诺生物制药股份有限公司 第四届监事会第一次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）第四届监事会 第一次会议于 2025 年 5 月 23 日下午 17:00 以现场与通讯会议方式召开。本次会 议应出席监事 3 人，实际出席会议监事 3 人。经全体监事同意，会议豁免通知时 限要求，以口头通知方式送达全体监事。本次会议由全体监事共同推举殷新波先 生主持，主持人在会议上就本次豁免通知事项进行了说明。会议的召开程序符合 有关 ...

Core Viewpoint - The announcement of the change in fund manager for "Yongying Hong Kong Stock Connect Quality Life Selected Mixed Fund" from Yan Qing to Jiang Weihua highlights a significant shift in management, with implications for fund performance and investor confidence [1][4]. Group 1: Fund Manager Change - Yan Qing, an experienced investment manager with 19 years in the securities industry, has stepped down from managing the largest fund under Yongying, which had a size of 619 million yuan as of March 31, 2025 [1][3]. - Jiang Weihua, who has only 1.81 years of experience as a fund manager, will take over the management of the fund, increasing his total managed assets to approximately 1.306 billion yuan [13][15]. Group 2: Fund Performance - The "Yongying Hong Kong Stock Connect Quality Life Selected Mixed Fund" has shown a year-to-date return of 9.99%, outperforming its benchmark of 9.94% and significantly surpassing the CSI 300 index's return of -1.47% [4][8]. - Despite the recent strong performance, the fund has underperformed its benchmark by 31.54% since inception, with a total return of -26.80% compared to the benchmark's 4.74% [6][8]. Group 3: Historical Performance Analysis - Yan Qing's management of the fund has been inconsistent, with annual returns showing significant underperformance against benchmarks in previous years, particularly from 2021 to 2024 [4][6]. - The fund's performance has raised concerns regarding the sustainability of returns, especially given the recent regulatory focus on long-term performance metrics for fund managers [4][6]. Group 4: Comparison of Fund Products - Jiang Weihua's other managed funds, such as "Yongying New Consumption Smart Selection," have shown strong performance with a year-to-date return of 20.41%, indicating a potential for better management outcomes [18][21]. - The divergence in performance between Jiang Weihua's funds suggests that stock selection and market conditions play a crucial role in fund performance, with specific stocks like Pop Mart and TCL Electronics contributing significantly to returns [21].

Group 1: Pharmaceutical and Biotech Industry - The pharmaceutical and biotech sector showed an overall increase of 1.27% from May 12 to May 16, outperforming the CSI 300 index by 0.15 percentage points [6] - The sector's year-to-date increase is 2.48%, ranking 11th among 31 industries, with a valuation of 27.01 times PE, which is at a historically low level [6] - Notable sub-sectors include Traditional Chinese Medicine, Medical Services, and Chemical Pharmaceuticals, with respective increases of 1.73%, 1.45%, and 1.44% [6] - The report highlights the impact of a U.S. executive order aimed at reducing prescription drug prices, which may lead to a shift in pricing strategies among global pharmaceutical companies [7] - Investment opportunities are suggested in innovative drug chains, medical devices, Traditional Chinese Medicine, and healthcare services [7][8] Group 2: Mergers and Acquisitions - The China Securities Regulatory Commission (CSRC) revised the management measures for major asset restructuring, enhancing market vitality [10] - Since the introduction of the "Six Guidelines" for mergers and acquisitions, over 1,400 asset restructuring cases have been disclosed, with significant increases in both the number and value of major transactions [10][26] - The new rules include mechanisms for installment payments for shares, simplified review processes, and increased participation from private equity funds [11][12][26] Group 3: Economic Data and Observations - In April 2025, the total retail sales of consumer goods increased by 5.1% year-on-year, while fixed asset investment grew by 4.0% [15] - Industrial production showed resilience with a year-on-year increase of 6.1%, despite a slight decline from previous months [15][16] - The report indicates a stable investment environment in infrastructure and manufacturing, although real estate continues to be a drag on overall growth [15][18] Group 4: Food and Beverage Industry - The food and beverage sector saw a modest increase of 0.48%, underperforming the CSI 300 index by 0.64 percentage points [20] - The report emphasizes the ongoing adjustments in the liquor industry, with companies exploring new channels and product innovations to navigate the seasonal downturn [21] - Investment recommendations include high-end liquor brands and resilient food companies, particularly in the snack and dairy segments [24] Group 5: Energy Storage Industry - The global energy storage market is experiencing significant growth, with a cumulative installed capacity of 372 GW in 2024, representing a year-on-year increase of 28.6% [30] - The report highlights the increasing share of new energy storage technologies, which accounted for 44.5% of total installations [30] - Investment opportunities are identified in leading companies with strong risk management capabilities, particularly in emerging markets [34]

Group 1 - The core index of the Shanghai Stock Exchange Science and Technology Innovation Board for innovative drugs remained flat, closing at 0.0 points with a trading volume of 0.0 billion yuan [1] - The index has shown a monthly increase of 0.15%, a three-month increase of 15.81%, and a year-to-date increase of 24.30% [1] - The index is composed of no more than 30 listed companies in the innovative drug sector, reflecting the overall performance of these companies on the Science and Technology Innovation Board [1] Group 2 - The top ten weighted companies in the index include: Bai Li Tianheng (10.7%), BeiGene (10.04%), Aier Pharmaceutical (9.31%), Zai Lab (8.4%), Junshi Biosciences (7.59%), Teruisi Biopharma (5.83%), Rongchang Biopharma (4.39%), Dize Pharmaceutical (3.81%), Nuotai Biopharma (3.52%), and Yifang Biopharma (3.45%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a sector breakdown of 49.12% in other biopharmaceuticals, 35.60% in pharmaceutical preparations, 11.83% in pharmaceutical and biotechnology services, and 3.46% in vaccines [1]

| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

Core Insights - Novo Nordisk's semaglutide has successfully claimed the title of "king of drugs" in Q1 2024, surpassing Merck's Keytruda in sales [2][3] - The success of semaglutide has sparked a research and development frenzy in the global weight loss market among multinational corporations (MNCs) [1][6] - The competitive landscape in the GLP-1 space is intensifying, particularly with Eli Lilly's strong performance and ongoing clinical trials [4][5] Sales Performance - In Q1 2024, Novo Nordisk's semaglutide products generated a total sales revenue of approximately $8.38 billion, with individual products Wegovy, Ozempic, and Rybelsus contributing $2.63 billion, $4.95 billion, and $0.86 billion respectively [2] - Merck's Keytruda reported Q1 sales of $7.2 billion, indicating that semaglutide has overtaken it in sales for the first time [2] Market Dynamics - Novo Nordisk has lowered its full-year performance outlook due to lower-than-expected penetration rates of its GLP-1 products in the U.S. market, despite achieving an 18% sales growth in Q1 [3] - Eli Lilly's GLP-1 products, Mounjaro and Zepbound, generated combined sales of $6.15 billion in Q1, indicating strong competition in the market [4] R&D Developments - Novo Nordisk is focusing on developing new formulations, with the oral version of Wegovy under FDA review, which could become the first oral GLP-1 treatment for long-term weight management if approved [5] - Pfizer has announced a commitment to weight loss drug development but faced setbacks with the termination of its oral GLP-1 drug Danuglipron due to safety concerns [6] CXO Industry Impact - The surge in GLP-1 research has positively impacted domestic CXO companies, with WuXi AppTec's TIDES business achieving a revenue of 5.8 billion yuan in 2023, a 70.1% increase year-on-year [7] - Notable growth has also been reported by Novotech Biopharma, with Q1 revenue of 566 million yuan, a 58.96% increase, and a projected annual revenue growth of nearly 60% for 2024 [7]

证券代码：688076 证券简称：诺泰生物 江苏诺泰澳赛诺生物制药股份有限公司 2024 年年度股东大会会议资料 二零二五年五月 江苏诺泰澳赛诺生物制药股份有限公司（688076） 2024 年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 年年度股东大会会议资料目录 2024 1 | | | --- | --- | | 2024 年年度股东大会会议须知 | 2 | | 2024 年年度股东大会会议议程 | 4 | | 议案一：关于《2024 年度董事会工作报告》的议案 | 6 | | 2024 年度独立董事述职报告（徐强国） 11 | | | 2024 年度独立董事述职报告（高集馥） 18 | | | 2024 年度独立董事述职报告（曲峰） | 24 | | 2024 年度独立董事述职报告（胡文言） 30 | | | 议案二：关于《2024 年度监事会工作报告》的议案 | 36 | | 议案三：关于《2024 年年度报告》及其摘要的议案 | 42 | | 议案四：关于《2024 年度财务决算报告》的议案 43 | | | 议案五：关于 2024 年度利润分配方案的议案 | 45 | | 议案 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2025-041 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ??会议召开时间：2025 年 5 月 26 日(星期一)下午 13:00-14:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ??投资者可于 2025 年 5 月 19 日(星期一)至 5 月 25 日(星期日)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinopep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 23 日发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者 更全面深入地了解公司 2024 年 ...

证券代码：688076 证券简称：诺泰生物 公告编号：2025-041 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 26 日(星期一)下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2025 年 5 月 26 日下午 13:00-14:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于 2025 年 5 月 19 日(星期一)至 5 月 25 日(星期日)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinopep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 江 ...